Lumida
/XNCR
⌘K
Xencor Inc

Xencor Inc

XNCR
$17.47USD↑+16.86%+2.52 today

MARKET CAP

1.3B

P/E (TTM)

—

FWD P/E

—

DAY RANGE

$15 – $18

52W RANGE

$7
$19

AI Summary

Stalk
StalkMedium

In the Stage 2 advancing phase, XNCR has broken out above resistance on expanding volume and remains in an uptrend, but is currently extended and overbought above rising EMAs. Medium-term bias is bullish, but short-term timing is unfavorable after the move. We will Stalk for a pullback into the 9EMA or 20EMA, where buy-side interaction is structurally appropriate.

  • ↑$697 million cash supports operations and trials through 2027
  • ↑XF819 showed 25% response rate and 70% disease control; Phase 3 starts 2024
  • ↓Negative profitability and earnings yield raise concerns over returns
Full analysis →

The case for & against

Bull & Bear analysis

Bullish

Zencore Bio, Inc. (NASDAQ: ZENC) is a groundbreaking biotechnology company focused on developing differentiated oncology therapies utilizing a proprietary protein engineering platform. The company is strategically positioning itself within the highly competitive oncology landscape through the advancement of its lead assets, particularly XF819 and XMAP541, which target solid tumors. Zencore is embracing the rising demand for targeted therapies in the oncology sector while addressing unmet patient needs in solid tumor treatment, utilizing its robust clinical development strategies.

Bull says

  • ↑$697 million cash supports operations and trials through 2027
  • ↑XF819 showed 25% response rate and 70% disease control; Phase 3 starts 2024
  • ↑Strategic pivot to lead T-cell engagers for NSCLC front-line treatment
  • ↑13F ownership score indicates strong institutional backing
  • ↑Potential $20 million milestone payment boosts near-term revenue
  • ↑Proprietary protein platform aims for best-in-class solid tumor therapies

Bear says

  • ↓Negative profitability and earnings yield raise concerns over returns
  • ↓Key XF819 and XMAP541 readouts risk delays or unfavorable outcomes
  • ↓Intense competition from Amgen, BMY, MRK, AZN in oncology T-cell space
  • ↓Overreliance on limited pipeline assets increases volatility
  • ↓Weak growth and profitability factors suggest cautious stance

Investment themes with XNCR

Biotech↓ -3.20%

Genetic and drug innovations driving medical breakthroughs

APLS · RVMD · SMMT

Earnings Call · Q1 2023 · Mgmt. Guidance

Updated 06-04-2026bullish

Transcript signals

Bull points

  • AD has still a significant unmet need, both for just the breadth of the number of severe patients as well as the need for longer acting agents.
  • We know that there's a lot of excitement about Leberkizumab coming on with a monthly, which is better than Dupilumab, which is every two weeks and is really bound by the target mediated clearance there.
  • We target novel biologies with our candidate designs, including CD28 co-stim bispecifics, more tumor-selective CD3 bispecifics, and potency-reduced cytokines.

Bear points

  • I think we made a point of adding atopic dermatitis into the Phase 1b mix, and we will be dosing patients in cohorts there as we step up a little bit in dose, because we do think
  • we just want to be as fast and as nimble and as quick about the decisions we make. Because it is, as you're right, a capital-constrained environment.
  • Well, first of all, I mean, in terms of, you know, disappointments, all we have is a, you know, something about, you know, assets being moved around. We actually don't have any of the data from that study yet, so it's really hard to interpret what that means.
Read full transcript analysis ›